London, December 19, 2024 — Founded in 2019, Bioniq is renowned for its personalized nutritional support based on blood biomarker data. This month, the company is set to elevate the supplements industry with a new hyper-personalized product, Bioniq Build Your Own, allowing members to design their own supplement formulas. This launch directly responds to demand from the US market and represents the company’s most significant product advancement since introducing Bioniq GO in 2023.
According to Bioniq internal health form data, up to 15% of individuals living with special health needs seek a product that allows them to select ingredients tailored to their health conditions. These consumers often struggle to find the exact dosages and ingredients they need in existing products on the market, leading them to turn to Bioniq for an ultimate solution.
The new product addresses allergies, vitamin and mineral intolerances, as well as other special health needs. Consumers can choose to follow a formula recommended by Bioniq, which leverages its world-leading algorithm and database of over 6 million biochemical data points. Alternatively, they can design their own formulas by selecting from over 50 nutrients, with the option to include or exclude specific ingredients. In both cases, Bioniq supplements are delivered in a patented granular dosage form, ensuring high bioavailability.
“Bioniq is the only company capable of offering an extensive list of vitamins, minerals and phytonutrients in flexible dosages, thanks to our AI-driven approach and innovative granular delivery system. We have been developing our dosage technology to ensure it complies with all necessary medical regulations, enabling consumers with chronic diagnoses or specific medical conditions to have autonomy in creating specific supplement blends tailored to their medical and physical requirements. We believe this unique approach will be in high demand among customers and medical institutions, helping to improve the quality of life for even more people,” said Oliver Motisi, Chief Product Officer of Bioniq.
Sold in over 70 countries and with its total user base growing more than 5x in 2024, Bioniq’s cutting-edge approach is backed by world-leading scientists and a patent-pending algorithm. Combining advanced blood biomarker analysis and self-reported health data, Bioniq creates 100% customized supplements designed to meet individual health needs, revolutionizing the way people approach personal health management.
The AI-powered, patent-pending Bioniq algorithm evaluates an individual’s height, weight, age, lifestyle, and health goals to precisely identify micronutrient imbalances. It provides tailored nutritional insights, daily nutrient support, 1:1 nutrition consultations, and educational resources.
The new initiative is part of Bioniq’s focus on product development and the implementation of its products for medical, wellness, and athletic institutions worldwide. Recently, Bioniq announced that global football legend Cristiano Ronaldo had made a significant investment in the company, bringing its total valuation to $82 million. Previously, Bioniq successfully closed Series B, which raised $15 million led by Principal Investors HV Capital and Unbound, two leading European VCs.
Bioniq’s capability to deliver quantifiable before-and-after snapshots of users’ nutrient needs and optimization progress has proven invaluable in its partnerships with leading health and sports institutions, including Lanserhof and UFC.
About Bioniq
Bioniq, launched in 2019 in London, UK, is the industry leader in offering AI-driven personalized supplements based on blood test data. After conducting years of testing, Bioniq has developed the largest of its kind proprietary biochemical database with blood test data from customers across 5 continents. Shipping globally, Bioniq has created unique formulas for over 100,000 users that incorporate components and dosages tailor-made to each individual’s nutrient deficiencies, as identified through their blood results.
%201.webp)
